Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Wake up with Breakfast news in your inbox every market ... which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity. Even with Eli Lilly's Mounjaro ...
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback